Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) announced positive top-line interim results for its double-masked, placebo-controlled Phase II clinical trial of Squalamine ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE